TGFb targeting therapeutic peptide - PeptiDream
Alternative Names: Transforming growth factor beta targeting therapeutic peptide - PeptiDreamLatest Information Update: 06 Jan 2023
At a glance
- Originator PeptiDream
- Class Antineoplastics; Peptides
- Mechanism of Action Transforming growth factor beta modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer; Unspecified
Most Recent Events
- 12 Dec 2022 TGFb targeting peptide therapeutic - PeptiDream is available for licensing as of 06 Dec 2022. https://www.peptidream.com/pipeline/progress-of-programs.html
- 06 Dec 2022 Early research in Cancer in Japan (Parenteral) before December 2022 (PeptiDream pipeline, December 2022)
- 06 Dec 2022 Early research in Unspecified in Japan (Parenteral) before December 2022 (PeptiDream pipeline, December 2022)